AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)

The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.

Illustration of bacteria on colorful background, model of bacteria, microbes, microorganisms,

The world needs more antibiotics and antifungal medicines to combat antimicrobial resistance (AMR), but without a big return on investment, drug makers need incentives to develop and commercialize new anti-infectives – and if the market won't provide them, the government may have to step in.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Pink Sheet